Targeted therapy before surgery for a type of jaw tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a type of jaw tumor called solid/multicystic ameloblastoma with the BRAF V600E gene change (tested by a special lab method)
- Your tumor is large enough that your doctors recommend removing a piece of the jawbone (segmental resection)
- The cancer has not spread to other parts of your body
- You are generally in good health (able to do daily activities) and your organs work well (kidney, liver, blood counts)
- You have not taken targeted drugs for BRAF or MEK before and are willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two targeted pills before surgery can shrink a rare jaw tumor (ameloblastoma) with a specific gene change, possibly allowing a less extensive operation. It compares this approach to surgery alone.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Hear when a new Ameloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.